Ameridose today announced a voluntary recall of any unexpired Ameridose products remaining in circulation. This action is in cooperation with the FDA and the Massachusetts Board of Registration in Pharmacy in seeking improvements in Ameridose’s sterility testing process.
The use of injectible products that are not sterile can represent a serious hazard to health and could lead to life-threatening injuries and/or death. Ameridose has not received any adverse reports related to the products subject to this recall and neither Ameridose nor the FDA has identified impurities in any Ameridose products.
Affected products can be identified by markings that indicate Ameridose by name or by its company logo. A complete list of subjected products can be found here. All customers are recommended to immediately examine their inventory and quarantine products subject to this recall.